Ginkgo Bioworks completes acquisition of Modulus Therapeutics' Cell Therapy Assets to bolster CAR Designs
Acquiring Company
Ginkgo Bioworks
Acquired Company
Modulus Therapeutics
BostonSeattleOtherManufacturingBiotechnologySustainabilitySoftwareScience And EngineeringManufacturingBiotechnologyTherapeuticsDescription
Ginkgo Bioworks, a leading platform for cell programming and biosecurity, has acquired the cell therapy platform assets of Modulus Therapeutics, with a key focus on strengthening next-generation CAR designs. The acquisition is expected to enhance Ginkgo's extensive cell therapy capabilities and support the development of improved T-cell and NK-cell based CAR therapies to treat various diseases.
Quick answer
Ginkgo Bioworks is acquiring Modulus Therapeutics, announced April 2, 2024. Ginkgo Bioworks is based in Boston, Massachusetts, United States.
- How much did Ginkgo Bioworks pay for Modulus Therapeutics?
- The deal value was not disclosed.
- What does Ginkgo Bioworks do?
- Ginkgo Bioworks is the leading horizontal platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to..
- Where are Ginkgo Bioworks and Modulus Therapeutics based?
- Ginkgo Bioworks is based in Boston, Massachusetts, United States. Modulus Therapeutics is based in Seattle, Washington, United States.
- Who are the decision-makers at Ginkgo Bioworks?
- Fundz holds 3 contacts at Ginkgo Bioworks. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Other recent acquisitions in Sustainability and Science And Engineering
Deals where the buyer or target shares a sector with this one, within 45 days, from Fundz verified event records.
- Ginkgo Bioworks completes acquisition of AgBiome's Platform Assets to expand biosecurity and ag biological discovery and development capabilities (April 11, 2024)
- Nuvation Bio Inc. completes acquisition of AnHeart Therapeutics Ltd. to enhance its oncology pipeline (April 10, 2024)
- Nuvation Bio to Acquire AnHeart Therapeutics in All-Stock Transaction (March 25, 2024)
- Ginkgo Bioworks Acquires Proof Diagnostics, Growing Gene Editing Service Offerings for its Customers (February 28, 2024)
- Abbvie To Acquire Landos Biopharma, Further Strengthening Its Portfolio In Inflammatory And Autoimmune Diseases (March 25, 2024)
- Bristol Myers Squibb completes acquisition of Karuna Therapeutics, Inc. to strengthen its neuroscience portfolio (March 18, 2024)
Who to call at Ginkgo Bioworks, and when
When Ginkgo Bioworks changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day Ginkgo Bioworks raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Ginkgo Bioworks, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Ginkgo Bioworks. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Ginkgo Bioworks makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired Modulus Therapeutics?
Modulus Therapeutics was acquired by Ginkgo Bioworks, based in Boston. The deal was reported on April 2, 2024. Ginkgo Bioworks is publicly traded (DNA) and operates in Other.
When did Ginkgo Bioworks acquire Modulus Therapeutics?
Ginkgo Bioworks's acquisition of Modulus Therapeutics was reported on April 2, 2024. Ginkgo Bioworks, a leading platform for cell programming and biosecurity, has acquired the cell therapy platform assets of Modulus Therapeutics, with a key focus on strengthening next-generation CAR designs. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Modulus Therapeutics do?
Modulus Therapeutics is a cell engineering company specialized in designing next-generation cell therapies for autoimmune diseases. The company employs a combinatorial approach to develop and screen cell therapy components, resulting in novel cell behaviors. It is privately held, operating in Manufacturing, and is based in Seattle.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.